Literature DB >> 9393635

How to diagnose chronic rejection. A study in porcine intestinal allografts.

P Kuusanmäki1, J Lauronen, T Paavonen, M Pakarinen, S Yilmaz, P Häyry, J Halttunen.   

Abstract

Porcine small bowel allografts were followed for 18 weeks during immunosuppression with cyclosporine-A (CyA), azatioprine and prednisone. The mucosal alterations noted at the 12th week were epithelial vacuolation and loss of Goblet cells. Moderate infiltration of inflammatory cells, mainly lymphocytes, was found in the lamina propria. In addition, a few grafts exhibited oedema and fibrosis. Vessels already showed endothelial swelling and intimal proliferation at the 12th week. In the submucosa, the infiltration of inflammatory cells was not present till the 18th week. Further changes in the mucosa at the 18th week were the blunting of villi, cuboidal epithelium, crypt abscesses and epithelial atrophy. The histological alterations of mucosa and lamina propria existing in the full thickness biopsies were mostly also detectable in mucosal biopsies, provided that multiple biopsies were taken. Thus these parameters analyzed from mucosal biopsy material are suitable for the diagnosis and monitoring of chronic small bowel rejection. In autopsy, the most prominent features were in the mesenterial arteries: intimal proliferation, vasculitis, proliferation of media and endothelial alterations. The activity of the mucosal disaccharidases maltase and sucrase remained near the initial level till the 12th week and had decreased markedly by the 18th week.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9393635     DOI: 10.1046/j.1365-3083.1997.d01-157.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  1 in total

1.  Effects of ileum transplantation and chronic rejection on absorption and synthesis of cholesterol in pigs.

Authors:  Mikko P Pakarinen; Pekka Kuusanmäki; Jouni Lauronen; Timo Paavonen; Jorma Halttunen
Journal:  Pediatr Surg Int       Date:  2003-10-22       Impact factor: 1.827

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.